File Download
  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Efficacy and safety of tofacitinib in the treatment of rheumatoid arthritis: a systematic review and meta-analysis

TitleEfficacy and safety of tofacitinib in the treatment of rheumatoid arthritis: a systematic review and meta-analysis
Authors
Issue Date2013
PublisherBioMed Central Ltd.
Citation
BMC Musculoskeletal Disorders, 2013, v. 14, p. 298:1-298:12 How to Cite?
AbstractBACKGROUND: Tofacitinib is a disease-modifying antirheumatic drug (DMARD) which was recently approved by US Food and Drug Administration (FDA). There are several randomised clinical trials (RCTs) that have investigated the efficacy and safety of tofacitinib in adult patients with rheumatoid arthritis (RA). A systematic review with a meta-analysis of RCTs was undertaken to determine the efficacy and safety of tofacitinib in treating patients with RA. METHODS: Electronic and clinical trials register databases were searched for published RCTs of tofacitinib between 2009 and 2013. Outcomes of interest include 20% and 50% improvement in the American College of Rheumatology Scale (ACR20 and ACR50) response rates, rates of infection, the number of immunological/haematological adverse events (AEs), deranged laboratory results (hepatic, renal, haematological tests and lipoprotein level) and the incidence of drug withdrawal. RESULTS: Eight RCTs (n = 3,791) were reviewed. Significantly greater ACR20 response rates were observed in patients receiving tofacitinib 5 and 10 mg bid (twice daily) versus placebo at week 12, with risk ratios (RR) of 2.20 (95% CI 1.58, 3.07) and 2.38 (95% CI 1.81, 3.14) respectively. The effect was maintained at week 24 for 5 mg bid (RR 1.94; 95% CI 1.55, 2.44) and 10 mg bid (RR 2.20; 95% CI 1.76, 2.75). The ACR50 response rate was also significantly higher for patients receiving tofacitinib 5 mg bid (RR 2.91; 95% CI 2.03, 4.16) and 10 mg bid (RR 3.32; 95% CI 2.33, 4.72) compared to placebo at week 12. Patients in the tofacitinib group had significantly lower mean neutrophil counts, higher serum creatinine, higher percentage change of LDL/HDL and a higher risk of ALT/AST > 1 ULN (upper limit of normal) versus placebo. There were no significant differences in AEs and withdrawal due to AEs compared to placebo. CONCLUSION: Tofacitinib is efficacious and well tolerated in patients with MTX-resistant RA up to a period of 24 weeks. However, haematological, liver function tests and lipoproteins should be monitored. Long-term efficacy and pharmacovigilance studies are recommended.
Persistent Identifierhttp://hdl.handle.net/10722/195549
ISSN
2015 Impact Factor: 1.684
2015 SCImago Journal Rankings: 0.881
PubMed Central ID
ISI Accession Number ID

 

DC FieldValueLanguage
dc.contributor.authorHe, Y-
dc.contributor.authorWong, AYS-
dc.contributor.authorChan, EWY-
dc.contributor.authorLau, WCY-
dc.contributor.authorMan, KC-
dc.contributor.authorChui, CSL-
dc.contributor.authorWorsley, AJ-
dc.contributor.authorWong, ICK-
dc.date.accessioned2014-03-04T06:00:29Z-
dc.date.available2014-03-04T06:00:29Z-
dc.date.issued2013-
dc.identifier.citationBMC Musculoskeletal Disorders, 2013, v. 14, p. 298:1-298:12-
dc.identifier.issn1471-2474-
dc.identifier.urihttp://hdl.handle.net/10722/195549-
dc.description.abstractBACKGROUND: Tofacitinib is a disease-modifying antirheumatic drug (DMARD) which was recently approved by US Food and Drug Administration (FDA). There are several randomised clinical trials (RCTs) that have investigated the efficacy and safety of tofacitinib in adult patients with rheumatoid arthritis (RA). A systematic review with a meta-analysis of RCTs was undertaken to determine the efficacy and safety of tofacitinib in treating patients with RA. METHODS: Electronic and clinical trials register databases were searched for published RCTs of tofacitinib between 2009 and 2013. Outcomes of interest include 20% and 50% improvement in the American College of Rheumatology Scale (ACR20 and ACR50) response rates, rates of infection, the number of immunological/haematological adverse events (AEs), deranged laboratory results (hepatic, renal, haematological tests and lipoprotein level) and the incidence of drug withdrawal. RESULTS: Eight RCTs (n = 3,791) were reviewed. Significantly greater ACR20 response rates were observed in patients receiving tofacitinib 5 and 10 mg bid (twice daily) versus placebo at week 12, with risk ratios (RR) of 2.20 (95% CI 1.58, 3.07) and 2.38 (95% CI 1.81, 3.14) respectively. The effect was maintained at week 24 for 5 mg bid (RR 1.94; 95% CI 1.55, 2.44) and 10 mg bid (RR 2.20; 95% CI 1.76, 2.75). The ACR50 response rate was also significantly higher for patients receiving tofacitinib 5 mg bid (RR 2.91; 95% CI 2.03, 4.16) and 10 mg bid (RR 3.32; 95% CI 2.33, 4.72) compared to placebo at week 12. Patients in the tofacitinib group had significantly lower mean neutrophil counts, higher serum creatinine, higher percentage change of LDL/HDL and a higher risk of ALT/AST > 1 ULN (upper limit of normal) versus placebo. There were no significant differences in AEs and withdrawal due to AEs compared to placebo. CONCLUSION: Tofacitinib is efficacious and well tolerated in patients with MTX-resistant RA up to a period of 24 weeks. However, haematological, liver function tests and lipoproteins should be monitored. Long-term efficacy and pharmacovigilance studies are recommended.-
dc.languageeng-
dc.publisherBioMed Central Ltd.-
dc.relation.ispartofBMC Musculoskeletal Disorders-
dc.rightsBMC Musculoskeletal Disorders. Copyright © BioMed Central Ltd.-
dc.rightsCreative Commons: Attribution 3.0 Hong Kong License-
dc.titleEfficacy and safety of tofacitinib in the treatment of rheumatoid arthritis: a systematic review and meta-analysisen_US
dc.typeArticleen_US
dc.identifier.emailChan, EWY: ewchan@hku.hk-
dc.identifier.emailWorsley, AJ: alanwor@hku.hk-
dc.identifier.emailWong, ICK: wongick@hku.hk-
dc.description.naturepublished_or_final_version-
dc.identifier.doi10.1186/1471-2474-14-298-
dc.identifier.pmid24139404-
dc.identifier.pmcidPMC3819708-
dc.identifier.hkuros239776-
dc.identifier.volume14-
dc.identifier.spage298:1-
dc.identifier.epage298:12-
dc.identifier.isiWOS:000328049600001-
dc.publisher.placeUnited Kingdom-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats